TSTickerStarGet alerts

ONCO 10-Q filed 2026-11-16 | Key takeaways

ONCO filed its 10-Q; the most relevant disclosure change is added ELOC commitment fee expense: The company recognized ELOC commitment fee expense of $30.4 million in Q3 2026, representing the excess of the $30.6 million fair value of Series F preferred stock issued over the $249,600 cash received, as the commitment fee for a $750 million equity line of.

Share this story

Key takeaways

  • Net loss: Q3 2026 loss of $31.6 million widened from $8.8 million in Q3 2025, primarily due to $30.4 million ELOC commitment fee expense.

  • Cash position: Cash decreased to $2.7 million as of September 30, 2026, from $5.2 million at December 31, 2025; the company used $5.8 million in operating activities during the nine months.

  • Series F preferred stock: On July 28, 2026, the company issued 37,812 Series F preferred shares with $30.6 million fair value as commitment for a $750 million ELOC; $30.4 million was expensed as a commitment fee.

  • Realbotix transaction: The share exchange agreement was amended on November 4, 2026 to extend the end date to March 31, 2027; the Grid Promissory Note to Realbotix totaled $3.0 million as of October 22, 2026.

  • Goodwill: Nine-month goodwill impairment of $8.6 million recognized; goodwill declined to $9.3 million from $18.5 million at year-end 2025.

  • Stockholders' equity: Turned negative at September 30, 2026 with a deficit of $17.3 million, compared to positive equity of $15.8 million at December 31, 2025.

  • Reverse stock split: A 1-for-10 reverse split was effected on November 6, 2026, following prior splits in March and May 2026.

Key metrics

Total revenueQ3 2026
$102,884-66%
Total revenue (YTD)Nine months ended September 30, 2026
$141,461-72%
Net lossQ3 2026
$31,627,931worsened from $8,783,702
Net loss (YTD)Nine months ended September 30, 2026
$38,710,109worsened from $19,702,029
Cash used in operating activities (YTD)Nine months ended September 30, 2026
$5,758,516improved from $6,587,805
Cash and cash equivalentsSeptember 30, 2026
$2,741,657down from $5,220,654 at December 31, 2025
GoodwillSeptember 30, 2026
$9,328,449down from $18,549,005 at December 31, 2025
Total assetsSeptember 30, 2026
$15,545,227down from $24,926,638 at December 31, 2025

Disclosure changes

  • ELOC commitment fee expense

    The company recognized ELOC commitment fee expense of $30.4 million in Q3 2026, representing the excess of the $30.6 million fair value of Series F preferred stock issued over the $249,600 cash received, as the commitment fee for a $750 million equity line of credit.

    This non-cash expense was the primary driver of the Q3 2026 net loss of $31.6 million and significantly impacted stockholders' equity, which turned negative.
  • Notes receivable from Realbotix

    The company advanced $2.5 million to Realbotix under a Grid Promissory Note as of September 30, 2026, with an additional $500,000 advanced on October 22, 2026, bringing the total to $3.0 million outstanding. The note is unsecured, matures September 11, 2027, and bears no interest unless the Share Exchange Agreement is terminated.

    This represents a significant use of cash and creates exposure to Realbotix's ability to repay if the transaction does not close. The note will be cancelled upon closing of the Realbotix acquisition.
  • Series F preferred stock

    On July 28, 2026, the company issued 37,812 shares of Series F preferred stock with a stated value of $1,000 per share and fair value of $30.6 million as commitment shares for a $750 million ELOC. The shares are classified in temporary equity. As of September 30, 2026, 37,562 shares remained outstanding with a carrying value of $28.8 million.

    This preferred stock contains provisions that could require cash payments if the company does not have sufficient authorized shares for conversion, creating potential liquidity risk. The fair value significantly exceeds cash received.
  • Stockholders' equity turned negative

    Total stockholders' equity turned negative at September 30, 2026, with a deficit of $17.3 million, compared to positive equity of $15.8 million at December 31, 2025. The accumulated deficit increased to $169.9 million from $131.2 million.

    Negative stockholders' equity indicates the company has more liabilities than assets and may face challenges in raising additional capital or maintaining compliance with debt covenants.
  • Realbotix transaction extension and amendment

    The Share Exchange Agreement with Realbotix was amended on November 4, 2026 to extend the end date to March 31, 2027 and modify the Net Cash definition to include the unpaid principal and accrued interest under the Grid Promissory Note. If Net Cash at closing is less than $12.5 million and parties proceed, the seller will own 95% of Fully Diluted Shares.

    The extension and amendment increase the likelihood of closing but at potentially significant dilution to existing stockholders if the company's Net Cash is below $12.5 million at closing.
  • Goodwill impairment

    The company recognized goodwill impairment of $8.6 million during the nine months ended September 30, 2026, reducing goodwill from $18.5 million at December 31, 2025, to $9.3 million. No impairment was recorded in Q3 2026. Impairment of $11.5 million was recorded in the same period of 2025.

    Ongoing goodwill impairments reflect declining market capitalization and may indicate further impairment risk if the company's stock price and market conditions do not improve.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow ONCO in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert